Table 1. Results of the prognostic value of platelet to lymphocyte ratio (PLR) for the survival of 1388 patients with lung cancer.

	Number of patients	OS				PFS
		Univariate		Multivariate		Univariate		Multivariate
		HR	p	HR	p	HR	p	HR	p
all patients	1388	1.451(1.187–1.774)	<0.001	1.405(1.147–1.722)	0.001	1.446(1.183–1.768)	<0.001	1.384(1.130–1.695)	0.002
sex
male	982	1.685(1.346–2.109)	<0.001	1.700(1.353–2.136)	<0.001	1.676(1.339–2.098)	<0.001	1.651(1.314–2.074)	<0.001
female	406	0.894(0.566–1.412)	0.632	0.709(0.446–1.127)	0.146	0.896(0.568–1.414)	0.637	0.728(0.458–1.155)	0.178
age
>65	373	1.665(1.195–2.321)	0.003	1.635(1.166–2.292)	0.004	1.665(1.195–2.320)	0.003	1.650(1.174–2.318)	0.004
≤65	1015	1.323(1.027–1.704)	0.031	1.280(0.990–1.653)	0.059	1.317(1.022–1.696)	0.033	1.249(0.967–1.613)	0.088
stage
I/II	933	1.550(1.186–2.024)	0.001	1.502(1.148–1.965)	0.003	1.548(1.185–2.022)	0.001	1.512(1.155–1.979)	0.003
III/IV	455	1.237(0.925–1.655)	0.152	1.318(0.979–1.774)	0.069	1.187(0.887–1.587)	0.248	1.256(0.934–1.688)	0.131
cancer type
NSCLC	1292	1.462(1.184–1.804)	<0.001	1.393(1.125–1.724)	0.002	1.462(1.185–1.804)	<0.001	1.380(1.115–1.707)	0.003
SCLC	96	1.412(0.719–2.776)	0.317	1.393(0.703–2.758)	0.342	1.343(0.683–2.639)	0.393	1.298(0.655–2.571)	0.454

P < 0.05 is considered to be significant. Abbreviation: HR: hazard ration, NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer, OS: overall survival; PFS: progression free survival.